Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
复制标题
DOI：
10.1128/jvi.01313-21
复制
发表时间：
2021-11-09
影响因子：
5.4
通讯作者：
Edwards DK
中科院分区：
文献类型：
--
作者：
Choi A;Koch M;Wu K;Dixon G;Oestreicher J;Legault H;Stewart-Jones GBE;Colpitts T;Pajon R;Bennett H;Carfi A;Edwards DK
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 变种的出现引发了人们对传播性增加以及某些变种部分逃避免疫的能力的日益担忧。与野生型 SARS-CoV-2 病毒（指定为 D614G）的中和相比，测试了按照初免-加强计划免疫 mRNA-1273 COVID-19 疫苗的参与者的血清针对多种 SARS-CoV-2 变体（包括关注变体 (VOC) 和感兴趣变体 (VOIs)）的中和活性。结果显示，对 B.1.1.7 (Alpha) 变体的中和效价影响极小，在统计学上不显着（与 D614G 相比降低了 1.2 倍）；其他 VOC，例如 B.1.351（Beta，包括 B.1.351-v1、B.1.351-v2 和 B.1.351-v3）、P.1（Gamma）和 B.1.617.2（Delta），与 D614G 相比，中和滴度显着降低，范围为 2.1 倍至 8.4 倍，但仍然容易受到mRNA-1273-引发血清中和。重要性 鉴于在 COVID-19 大流行期间全球记录了 SARS-CoV-2 的多种变种，持续评估现有疫苗针对新出现的变种提供保护的能力仍然很重要。本文提供的数据表明，使用 mRNA-1273 COVID-19 疫苗进行免疫可产生针对所测试的关键新出现变体（包括关注变体和感兴趣变体）的中和抗体。虽然 mRNA-1273 针对大多数测试变体引起的血清中和作用与针对野生型病毒的血清中和作用相比有所降低，但预计中和水平仍具有保护性。此类数据对于为当前和未来的 COVID-19 疫苗接种策略提供信息至关重要。
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.